Clinical Trial Update: A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure. [Phase 3]

View source ↗

Summary

A Phase 3 dose-ranging trial evaluated the safety and efficacy of aliskiren at 150 mg, 300 mg, and 600 mg versus placebo in patients with hypertension; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis | Conditions: Hypertension | Phase 3 | Status: COMPLETED